Omada Health (OMDA): An 80/30 Margin Promise Behind a 4x Sales Premium

Omada Health spent its first investor day as a public company on September 10 handing Wall Street the biggest numbers it has ever put in writing: at least 20% annual revenue growth, an 80% non-GAAP gross margin, and a 30% adjusted EBITDA margin once the model scales out. The market's answer was a shrug — shares added only about 2.5%, to near $22,and have since faded below their 50-day average. For a company that just promised an extra roughly 30 points of EBITDA margin, the question worth asking is why nobody ran with it. The answer sits in the factor stack: the story is credible in the data, but the market has largely decided it's already priced in.

The 80/30 promise

Omada is the virtual-first, between-visit chronic-care provider — online programs for prediabetes, diabetes, hypertension, musculoskeletal, and behavioral health, sold to employers and health plans. It went public in June 2025 and is still very much an early-stage operator by the numbers that matter. An adjusted EBITDA margin target of 30% is not a slogan; it's a demand for operating leverage. Today the company runs at roughly a negative trailing EBITDA margin. Closing a gap that wide is the entire debate, and management's case rests on a conversion that is already partly visible on the tape.

Management laid out the bridge: non-GAAP gross margin had expanded from about 60% in fiscal 2023 to roughly 70% by the second quarter of 2026, and the 80% target is meant to come roughly equally from revenue and product mix and from cost-of-revenue efficiencies. The members base multiplied in the same window, from about 0.3 million to 1.09 million,with revenue climbing from roughly $123 million to $310 million. That is a company arguing it can keep growing at 20% or better even as it gets large — the growth claim has a track record behind it.

The improving report card

Strip away the investor-day staging and the underlying factor grades are genuinely getting better — this looks like an improving report card rather than a static one.

Growth is the easy grade, an A: second-quarter revenue of $88 million was up 43% year over year against the 20% floor, and management raised full-year 2026 revenue guidance to a $334–340 million range. Profitability is where the narrative and the data finally agree. Omada swung to about $5 million of net income in the second quarter against a $5 million loss a year earlier, its gross margin hit a record near 73%, and it has turned free-cash-flow positive at roughly $17 million over the trailing twelve months — the first time this company's economics read as a going concern rather than a growth subsidy. The balance sheet backs that up: about $222 million in cash, no net debt, and a current ratio near 390%.

That's a real change. A company that was burning cash through two painful clinic-heavy quarters two years ago has flipped to record gross margin, positive net income, and positive free cash flow inside a few quarters — precisely the "weak to decent" trajectory the factor framework treats as more actionable than a static top score.

The premium already prices it

Here is where the sector-relative read matters more than the scorecard. Omada trades at roughly 4.3 times trailing sales. Hims & Hers, the growth-stock poster child of virtual care, sits near 2.5 times; Teladoc, the category's cautionary tale, is around 0.4 times. In that comparison set, Omada is priced as the best of a category where both the champion and the cautionary tale teach the same lesson: growth in virtual care does not automatically convert to margin.

The 30% adjusted EBITDA target is the reason for the premium. Believe it closes and 4 times sales is defensible for a company this safe and this fast. Doubt it, and the multiple has a long way to fall — which is why the stock's reaction was so calm. It was being asked to confirm an expectation, not to reward a surprise.

The tape shows the tension. OMDA is up around 36% year to date and roughly 54% over the past four months, yet it has pulled back to sit below its 50-day average with RSI near 42 — a stock that ran, then paused to demand proof. There is also a leadership handoff to weigh into the calculus: co-founder Sean Duffy moves to executive chair and Wei-Li Shao becomes chief executive on January 1, 2027, an announcement that came alongside the record quarter.

Sizing the trade

In portfolio terms this is the quality-growth sleeve of a barbell — a cash-rich, capital-light compounder that is only now turning profitable. Its role is upside with a defined price: you are paying a premium for the 80/30 conversion, so it deserves to be sized like a growth position and paired with durable cash-flow or dividend names rather than leaned on for stability. The uncertainty is real, and the answer to that uncertainty is structure, not louder conviction.

The trigger that changes the call is specific and observable: watch whether non-GAAP gross margin walks from roughly 70% toward 80% quarter by quarter, and whether 20%-plus growth survives as the base gets bigger. If the margin path stalls or growth slips below the 20% floor, the premium becomes a compression risk fast. If the margin path holds, the premium is simply the price of owning the conversion before it finishes paying out.